MCRB Seres Therapeutics Inc.

5.24
+0.25  (+5%)
Previous Close 4.99
Open 5.13
52 Week Low 2.15
52 Week High 6.585
Market Cap $380,419,300
Shares 72,599,103
Float 35,066,554
Enterprise Value $330,996,523
Volume 813,379
Av. Daily Volume 541,615
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
SER-287
Mild-to-Moderate Ulcerative Colitis
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
SER-401
Melanoma
Phase 1b
Phase 1b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. – Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres' microbiome therapeutic pipeline –

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Young brings to Seres over 20 years of commercial and marketing leadership experience, having successfully led the growth of several important biopharmaceutical products.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005155/en/

    Terri Young, Ph.D., R.Ph. (Photo: Business Wire)

    Terri Young, Ph.D., R.Ph. (Photo: Business Wire)

    "We are thrilled to welcome Terri to the Seres…

    – Dr. Young to strengthen commercial expertise ahead of SER-109 Phase 3 data readout, and to maximize the potential of Seres' microbiome therapeutic pipeline –

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Young brings to Seres over 20 years of commercial and marketing leadership experience, having successfully led the growth of several important biopharmaceutical products.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005155/en/

    Terri Young, Ph.D., R.Ph. (Photo: Business Wire)

    Terri Young, Ph.D., R.Ph. (Photo: Business Wire)

    "We are thrilled to welcome Terri to the Seres team ahead of our anticipated, potentially pivotal SER-109 ECOSPOR III Phase 3 study readout in patients with recurrent C. difficile infection. Terri's extensive marketing and sales leadership experience will be invaluable as we continue to prepare for the potential commercialization of SER-109," said Eric Shaff, President and Chief Executive Officer of Seres. "In addition to SER-109, Terri will support the advancement of our overall microbiome therapeutic pipeline targeting infectious diseases, immunological conditions and cancer. In particular, we look forward to Terri's contributions on our promising SER-287 program, which is in a Phase 2b study for ulcerative colitis."

    "I am excited to join Seres as the Company prepares for the potential commercialization of SER-109. Recurrent C. difficile is a condition where improved treatment options are urgently needed, and SER-109 has the potential to fundamentally transform how patients are managed," said Dr. Young. "In addition to SER-109, Seres is advancing an innovative pipeline of microbiome therapeutic candidates, including SER-287 and SER-301 for ulcerative colitis and SER-401 and SER-155 for cancer. I look forward to working with the team to implement strategies that maximize the enormous potential of this novel therapeutic modality."

    Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage's global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company's largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company's Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen's Association, and served on the Advisory Board of the Healthcare Businesswomen's Association.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing and results of each of Seres' clinical studies, Seres'commercialization plans, the promise and potential impact of microbiome therapeutics and other statements that are not historical facts.

    These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: We have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; the ability to develop and commercialize our product candidates, if approved; the potential impact of the COVID-19 pandemic; our ability to retain key personnel and to manage our growth; and that our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 7, 2020 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    View Full Article Hide Full Article
  2. Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 9th at 2:10 p.m. ET.

    A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function…

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present a corporate overview at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on Tuesday, June 9th at 2:10 p.m. ET.

    A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

    View Full Article Hide Full Article
  3. Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET.

    A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced…

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present a corporate overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET.

    A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

    View Full Article Hide Full Article
  4. – Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020 –

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will host a virtual webcast symposium focused on SER-109 as a potential new therapeutic option for recurrent Clostridioides difficile infection (CDI) on Wednesday, May 27, 2020 from 8:30 to 9:30 a.m. ET.

    During the event, Mark Wilcox, M.D., Professor of Medical Microbiology, University of Leeds, and Seres' management will discuss the CDI patient burden, the ongoing SER-109 Phase 3 ECOSPOR III study and the potential for SER-109 to become the standard of care for recurrent CDI.

    SER-109 is being evaluated in an ongoing Phase 3 study for the prevention of recurrence of CDI. SER-109 has obtained…

    – Data from SER-109 Phase 3 study in recurrent C. difficile infection expected mid-2020 –

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will host a virtual webcast symposium focused on SER-109 as a potential new therapeutic option for recurrent Clostridioides difficile infection (CDI) on Wednesday, May 27, 2020 from 8:30 to 9:30 a.m. ET.

    During the event, Mark Wilcox, M.D., Professor of Medical Microbiology, University of Leeds, and Seres' management will discuss the CDI patient burden, the ongoing SER-109 Phase 3 ECOSPOR III study and the potential for SER-109 to become the standard of care for recurrent CDI.

    SER-109 is being evaluated in an ongoing Phase 3 study for the prevention of recurrence of CDI. SER-109 has obtained both Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).

    Seres previously reported the completion of enrollment in the Phase 3 ECOSPOR III study (ClinicalTrials.gov identifier: NCT03183128), a multicenter, randomized 1:1, placebo-controlled study in patients with multiply recurrent CDI. ECOSPOR III has enrolled 182 patients. Seres expects to report SER-109 Phase 3 top-line results in mid-2020.

    Based on prior discussions with the FDA, Seres believes that ECOSPOR III has the potential to be the single pivotal study supporting product registration; however, this will depend on the strength of the data, and additional safety data may be required. If approved, SER-109 has the potential to be the first FDA-approved therapy for CDI to treat the underlying cause of this disease, and the first approved microbiome drug for any human condition.

    To join the live webcast, on May 27, 2020 at 8:30 a.m. ET, including presentation slides, please visit the "Investors & Media" section of the Seres website at www.serestherapeutics.com. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 4884302. Webcast Link: https://edge.media-server.com/mmc/p/3qo4hxiv.

    A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing and results of our clinical studies, the potential for ECOSPOR III to serve as a pivotal trial to enable a BLA submission, the potential impact of SER-109 and other statements that are not historical facts.

    These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates and develop and commercialize our product candidates, if approved; the impact of the COVID-19 pandemic; our ability to retain key personnel and to manage our growth; and our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 7, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    View Full Article Hide Full Article
  5. Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.

    To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9143286. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com.

    A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome…

    Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.

    To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9143286. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com.

    A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

    About Seres Therapeutics

    Seres Therapeutics, Inc., (NASDAQ:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres' SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres' SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma and SER-301 for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

    View Full Article Hide Full Article
View All Seres Therapeutics Inc. News